查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2015192

核酸檢測市場：全球市場按產品類型、技術、檢體類型、應用和最終用戶分類的預測——2026-2032年

Nucleic Acid Testing Market by Product Type, Technology, Sample Type, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025年核酸檢測市場價值為104.7億美元，預計到2026年將成長至113.3億美元，複合年成長率為9.50%，到2032年將達到197.7億美元。

主要市場統計數據
基準年 2025 104.7億美元
預計年份：2026年 113.3億美元
預測年份 2032 197.7億美元
複合年成長率 (%) 9.50%

簡要說明技術、法規和資料管治的融合如何改變核酸檢測在各領域的部署。

核酸檢測已從一項小眾的實驗室應用發展成為一項涵蓋臨床診斷、生命科學研究和生物防禦等領域的基礎技術。近年來，檢測化學、樣品製備流程和數位訊號處理技術的進步顯著提高了分析靈敏度和處理能力，並縮短了檢測結果的獲取時間。這種轉變使得核酸檢測的應用範圍從集中式分子檢查室擴展到照護現場（POC​​）、分散式臨床試驗和環境監測舉措。

模組化設備、人工智慧驅動的分析以及確保穩定供應的試劑策略如何推動去中心化分子診斷進入新時代。

核酸檢測領域正經歷著一場變革性的轉變，這得益於儀器小型化、人工智慧分析和檢測化學多樣化的融合。小型化降低了去中心化的門檻，使得儀器能夠處理少量檢體並簡化操作流程，從而適用於門診和患者現場檢測。同時，機器學習模型正被整合到訊號處理流程中，從而提高了準確性，減少了假陽性，並實現了自動化品管，即使在非專業環境下也能獲得可靠的檢測結果。

對關稅政策變化如何影響整個分子檢測供應鏈的製造在地化、籌資策略和採購韌性進行定性分析。

影響進口實驗室設備、試劑和耗材的政策調整和關稅措施對核酸檢測的供應鏈設計和籌資策略有顯著影響。關稅上調會提高精密光學元件、 聚合酵素連鎖反應熱迴圈儀和特殊酵素等關鍵零件的到貨成本，進而影響設備和試劑盒生產商的採購決策。為此，一些供應商正在加快關鍵生產流程的本地化，並對替代供應商進行認證，以降低跨境關稅波動帶來的風險。

策略性細分揭示了產品類型、技術模式、檢體矩陣、應用案例和最終用戶實際情況如何共同決定機會和優先事項。

對產品類型趨勢的洞察揭示了儀器、試劑/試劑盒和軟體/服務的不同需求促進因素。儀器的部署與處理能力需求和部署環境密切相關，而試劑/試劑盒的需求則受檢測穩健性、儲存穩定性和供應連續性的影響。軟體和服務正日益透過資料分析、法規支援和工作流程整合創造價值，從而實現除一次性耗材之外的持續收入。從技術角度來看，數位PCR和次世代定序在複雜應用中展現出高靈敏度和多重分析能力，而等溫擴增和即時PCR因其快速且經濟高效的診斷方法而仍然具有吸引力。微陣列平台在特定的基因組篩檢和研究領域繼續發揮至關重要的作用，其預先定義的探針組能夠提供高效的標靶分析。

區域間在基礎建設、法規結構和公共衛生優先事項上的差異，如何影響產品引進和市場進入策略的差異化？

區域趨勢持續影響著核酸檢測領域相關人員的產品策略和市場進入方式。美洲地區擁有先進的檢查室基礎設施和快速發展的臨床網路，有利於高通量平台、整合IT系統和完善的監管流程。這種環境支持精準腫瘤檢測和高通量傳染病檢查等複雜應用，同時也對資料安全和保險報銷制度的合規性提出了更高的要求。

優先考慮競爭動態、可重複性、供應彈性和卓越服務，並透過平台創新、協作生態系統和整合策略來實現。

核酸檢測產業的企業發展趨勢呈現出平台創新、策略夥伴關係和垂直整合並存的特性。領先的儀器開發人員持續投資，致力於拓展檢測產品線、提高檢測通量並縮短檢測時間；而試劑盒和試劑生產商則專注於配方穩定性和簡化工作流程，以拓寬應用場景。軟體和服務供應商的角色日益凸顯，他們透過提供資料分析、品質保證和法規文件等服務，與以硬體為中心的產品和服務形成互補，並深化客戶關係。

為領導企業提供可操作且有影響力的策略措施，以加速採用、增強供應鏈韌性並實現整合硬體和軟體產品的獲利。

領導企業應優先考慮以下幾項切實可行的策略，以克服複雜性並實現永續成長。首先，投資於模組化平台架構，以實現快速添加檢測項目並輕鬆檢驗所有檢體類型。模組化設計可縮短產品開發前置作業時間，並能快速回應突發的公共衛生需求。其次，制定緊急時應對計畫鏈應急計劃，包括雙供應商模式、關鍵部件的本地化生產方案以及策略性庫存管理政策，以應對關稅波動和物流中斷。

採用多方面、交叉檢驗的研究途徑，結合專家訪談、技術文獻和監管趨勢，確保整合可靠的知識和可行的建議。

本研究結合了對儀器製造、試劑開發、臨床檢查室和監管事務領域意見領袖的定性訪談，並輔以對同行評審文獻、技術白皮書和政策指南的系統性二次分析。調查方法強調交叉驗證，透過將相關人員的觀點與已記錄的產品規格和已發表的檢驗研究進行三角檢驗。訪談重點在於產品開發藍圖、監管策略、生產依賴性和顧客接受度挑戰，使分析立足於實際情況。

一份權威的綜合分析報告，強調了將技術卓越性、營運韌性和協作商業化相結合的必要性。

總之，核酸檢測正處於一個轉折點，技術進步、監管成熟和採購重點的轉變正在重塑診斷技術的開發、檢驗和交付方式。模組化儀器、靈活的試劑策略和軟體驅動的分析技術的相互作用，正在催生新的經營模式，這些模式強調互通性、所有檢體類型均可重複的性能以及強大的售後服務能力。那些能夠根據當地監管環境調整產品設計並投資於供應鏈柔軟性的相關人員，將更有能力將技術能力轉化為臨床和商業性成果。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：核酸檢測市場：依產品類型分類

  • 裝置
  • 試劑和試劑盒
  • 軟體服務

第9章：核酸檢測市場：依技術分類

  • 數位PCR
  • 等溫擴增
  • 微陣列
  • 次世代定序
  • 即時PCR

第10章：依檢體類型分類的核酸檢測市場

  • 血
  • 唾液
  • 棉花棒
  • 組織
  • 尿

第11章：核酸檢測市場：依應用領域分類

  • 臨床診斷
  • 藥物發現
  • 法醫學
  • 研究
  • 獸醫診斷

第12章：核酸檢測市場：依最終用戶分類

  • 學術研究機構
  • 診斷檢測實驗室
  • 醫院和診所
  • 製藥和生物技術公司

第13章：核酸檢測市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章：核酸檢測市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 核酸檢測市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國核酸檢測市場

第17章：中國核酸檢測市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • Agilent Technologies, Inc.
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • bioMerieux SA
  • Danaher Corporation
  • F. Hoffmann-La Roche Ltd.
  • Hologic, Inc.
  • Illumina, Inc.
  • PerkinElmer, Inc.
  • QIAGEN NV
  • Quest Diagnostics Incorporated
  • Seegene Inc.
  • Siemens Healthineers AG
  • Thermo Fisher Scientific Inc.
Product Code: MRR-036C5CF3B554

The Nucleic Acid Testing Market was valued at USD 10.47 billion in 2025 and is projected to grow to USD 11.33 billion in 2026, with a CAGR of 9.50%, reaching USD 19.77 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 10.47 billion
Estimated Year [2026] USD 11.33 billion
Forecast Year [2032] USD 19.77 billion
CAGR (%) 9.50%

A concise primer on how technological, regulatory, and data governance convergences are reshaping nucleic acid testing adoption across sectors

Nucleic acid testing has evolved from a laboratory niche to a foundational technology across clinical diagnostics, life sciences research, and biodefense. Recent advances in assay chemistry, sample preparation workflows, and digital signal processing have increased analytical sensitivity and throughput while reducing time to result. This transformation has expanded the range of use cases beyond centralized molecular labs into point-of-care settings, decentralized clinical trials, and environmental surveillance initiatives.

As technologies have matured, regulatory bodies have increasingly harmonized validation expectations for molecular assays and platforms, enabling clearer pathways for clinical adoption. At the same time, developers are integrating software-driven analytics and cloud-enabled data management to enhance interpretability and compliance. Consequently, stakeholders must navigate a landscape where technological capability, regulatory alignment, and data governance converge to determine the pace at which new offerings reach patients, researchers, and public health programs.

Given these dynamics, strategic planners should focus on interoperability, assay robustness across diverse sample types, and scalable manufacturing of reagents and consumables. In parallel, investors and advisors are evaluating platform extensibility, downstream data services, and partnerships that bridge laboratory and clinical workflows. Transitioning from capability demonstrations to sustained clinical utility remains the central challenge and opportunity for organizations active in nucleic acid testing.

How modular instruments, AI-driven analytics, and supply-resilient reagent strategies are catalyzing a new era of decentralized molecular diagnostics

The nucleic acid testing landscape is undergoing transformative shifts driven by the convergence of miniaturized instrumentation, AI-enabled analytics, and expanded assay chemistries. Miniaturization has lowered barriers to decentralization, enabling devices that operate with reduced sample volumes and simplified workflows suitable for outpatient clinics and near-patient settings. Concurrently, machine learning models are being integrated into signal processing pipelines to improve accuracy, reduce false positives, and support automated quality control, thereby enabling higher-confidence results in non-specialist environments.

Platform modularity is another defining trend. Manufacturers are designing instruments with swappable assay modules and open software architectures to accommodate emergent pathogen targets and multiplexed testing needs. This design philosophy supports faster response to public health threats and more efficient product lifecycle management. Additionally, reagent manufacturers are focusing on lyophilized chemistries and room-temperature stable kits to address supply chain fragility and logistical constraints in varied geographies.

Finally, there is a rising emphasis on end-to-end solutions that integrate sample collection, cloud-based data management, and clinical decision support. These holistic offerings are elevating the role of software and services within the traditional diagnostics value chain, creating new recurring revenue opportunities while also raising data privacy and interoperability considerations that organizations must proactively address.

Qualitative analysis of how tariff policy shifts influence manufacturing localization, sourcing strategies, and procurement resilience across the molecular testing supply chain

Policy adjustments and tariff actions affecting imported laboratory equipment, reagents, and consumables have material implications for supply chain design and procurement strategies in nucleic acid testing. Increased tariffs raise the landed cost of key components such as precision optics, thermal cyclers, and specialty enzymes, which in turn influences the sourcing decisions of instrument makers and kit manufacturers. In response, some suppliers accelerate localization of critical manufacturing steps or qualify alternative suppliers to mitigate exposure to cross-border tariff volatility.

Tariff-driven cost pressures also incentivize product redesigns that reduce dependence on tariff-exposed inputs through component substitution, consolidation of supplier bases, or migration to standardized, locally sourced parts. These strategic shifts can improve resilience but may require upfront investments in revalidation and quality management to ensure assay performance remains uncompromised. For end users, procurement cycles are lengthening as organizations weigh total cost of ownership, service coverage, and supply continuity rather than relying solely on unit price.

Moreover, policy uncertainty encourages greater emphasis on contractual protections, dual-sourcing strategies, and inventory buffering for critical reagents. As a result, stakeholders who proactively assess tariff exposure and implement adaptive sourcing and manufacturing approaches enhance their market agility and reduce downstream operational disruptions in testing workflows.

Strategic segmentation reveals how product type, technology modality, sample matrices, application use cases, and end-user realities jointly define opportunity and prioritization

Insight into product type dynamics reveals distinct demand drivers for instruments, reagents and kits, and software and services. Instrument adoption is closely tied to throughput requirements and deployment setting, while reagents and kits are governed by assay robustness, storage stability, and supply continuity. Software and services increasingly capture value through data analytics, regulatory support, and workflow integration, enabling recurring revenue beyond single-use consumables. When examined by technology, digital PCR and next generation sequencing offer high sensitivity and multiplexing capabilities for complex applications, while isothermal amplification and real-time PCR remain attractive for rapid, cost-effective diagnostics. Microarray platforms retain relevance in certain genomic screening and research contexts where predefined probe panels provide efficient target analysis.

Sample type considerations shape assay design and user experience across blood, saliva, swabs, tissue, and urine. Blood-based assays typically prioritize analytical sensitivity and standardized collection, whereas saliva and swab-based approaches emphasize ease of collection and stability. Tissue and urine assays open specialized diagnostic windows that require tailored extraction and matrix-specific validation. Application areas such as clinical diagnostics, drug discovery, forensics, research, and veterinary diagnostics each impose unique regulatory, throughput, and data-interpretation requirements that influence product roadmaps. End-user segments including academic research institutes, diagnostic laboratories, hospitals and clinics, and pharmaceutical and biotechnology companies differ in purchasing cadence, emphasis on regulatory compliance, and openness to integrated software-driven solutions.

Taken together, these segmentation lenses demonstrate that success in nucleic acid testing depends on aligning product development with the intersection of technological capability, sample-preparation constraints, and the operational realities of distinct end users. Product teams should therefore prioritize modular platforms, validated workflows for diverse sample matrices, and flexible commercial models that reflect the needs of both research-focused and clinical-facing customers.

How distinct regional infrastructure, regulatory frameworks, and public health priorities are shaping differentiated strategies for product adoption and market access

Regional dynamics continue to influence product strategies and go-to-market approaches for nucleic acid testing stakeholders. The Americas feature advanced laboratory infrastructure and fast-adopting clinical networks that favor high-throughput platforms, integrated IT systems, and comprehensive regulatory pathways. This environment supports complex applications such as precision oncology assays and high-volume infectious disease testing, while also demanding stringent data security and reimbursement alignment.

Europe, the Middle East and Africa present a more heterogeneous landscape, where pockets of regulatory harmonization coexist with varying levels of laboratory infrastructure. In many EMEA markets, buyers value robust supply chains, reagent stability, and solutions that can be validated across multiple regulatory jurisdictions. Partnerships with local distributors and investments in training and service logistics help overcome fragmentation and accelerate adoption in both clinical and veterinary settings.

Asia-Pacific displays rapid adoption of point-of-care and decentralized testing solutions driven by public health priorities, investments in local manufacturing, and large-scale research initiatives. Diverse healthcare delivery models across the region require adaptable product configurations, multilingual software interfaces, and flexible financing arrangements. Across all regions, interoperability, supply resilience, and alignment with local regulatory expectations remain essential considerations for sustained market access and commercial success.

Competitive dynamics driven by platform innovation, collaborative ecosystems, and integration strategies that prioritize reproducibility, supply resilience, and service excellence

Company behavior in the nucleic acid testing domain is characterized by a mix of platform innovation, strategic partnerships, and vertical integration. Leading instrument developers continue to invest in expanding assay menus, improving throughput, and shortening time to result, while kit and reagent producers focus on formulation stability and simplified workflows to broaden use cases. Software and services providers are increasingly critical, offering data analytics, quality assurance, and regulatory documentation that augment hardware-centric offerings and deepen customer relationships.

Collaborative models are prominent, with diagnostic developers partnering with academic centers, contract manufacturers, and software integrators to accelerate validation and scale production. These alliances help spread risk and reduce time to market for complex assays, particularly when navigating multi-jurisdictional regulatory environments. At the same time, some players pursue backward integration to secure critical reagent supplies or forward integration to offer bundled testing solutions that include sample collection, analytics, and reporting.

Competitive differentiation increasingly rests on service excellence, regulatory expertise, and the ability to deliver reproducible performance across diverse sample types and laboratory settings. Organizations that combine robust technical performance with dependable global supply chains and proactive customer support are best positioned to capture adoption across clinical, research, and applied diagnostic segments.

Practical, high-impact strategic moves for leaders to accelerate adoption, fortify supply chain resilience, and monetize integrated hardware-software offerings

Leaders in nucleic acid testing should prioritize several actionable strategies to navigate complexity and unlock sustained growth. First, invest in modular platform architectures that enable rapid assay additions and ease of validation across sample types. Modular designs reduce product development timelines and allow quicker responses to emergent public health needs. Second, develop supply chain contingency plans that include dual sourcing, local manufacturing options for critical components, and strategic inventory policies to buffer against tariff volatility and logistic disruptions.

Third, enhance value propositions by pairing hardware with cloud-enabled analytics, regulatory support services, and training programs that reduce friction in customer adoption. Such integrated offerings increase stickiness and create recurring revenue streams. Fourth, pursue targeted partnerships with academic, clinical, and manufacturing organizations to share validation burden and accelerate market entry in fragmented regulatory jurisdictions. Finally, embed privacy-by-design and interoperability standards into software roadmaps to meet growing expectations around data governance and clinical integration.

By executing on these priorities, organizations can balance innovation speed with the operational rigor required for clinical adoption, thereby converting technical capability into lasting market relevance.

A multi-source, triangulated research approach combining expert interviews, technical literature, and regulatory signals to ensure robust insight synthesis and actionable recommendations

This research synthesizes primary qualitative interviews with thought leaders across instrument manufacturing, reagent development, clinical laboratories, and regulatory affairs, complemented by systematic secondary analysis of peer-reviewed literature, technical white papers, and policy guidance. The methodology emphasizes cross-validation of insights by triangulating stakeholder perspectives with documented product specifications and published validation studies. Interviews focused on product development roadmaps, regulatory strategies, manufacturing dependencies, and customer adoption challenges to ground analysis in operational realities.

Secondary sources included reagent and platform technical notes, clinical validation reports, and public regulatory communications to ensure that conclusions reflect verifiable performance characteristics and compliance expectations. The analytical framework structured findings across technology modality, sample matrix, application area, and end-user profile, enabling targeted recommendations that map to distinct strategic decisions. Finally, an iterative review process involving subject-matter experts ensured interpretive rigor and reduced the risk of bias, while supplemental sensitivity checks examined alternative scenarios for supply chain and regulatory developments.

A conclusive synthesis that emphasizes the necessity of marrying technical excellence with operational resilience and collaborative commercialization to achieve durable impact

In conclusion, nucleic acid testing sits at an inflection point where technical advances, regulatory maturation, and evolving procurement priorities are reshaping how diagnostics are developed, validated, and delivered. The interplay between modular instrumentation, resilient reagent strategies, and software-enabled analytics is creating new commercial models that reward interoperability, reproducible performance across sample types, and strong post-sale service capabilities. Stakeholders that align product design with regional regulatory realities and invest in supply chain flexibility will be best positioned to translate technical capability into clinical and commercial impact.

Moving forward, organizations should treat data governance, assay robustness, and customer enablement as core elements of product value rather than adjunct considerations. In doing so, they will not only enhance adoption rates but also build the institutional trust necessary for long-term integration into clinical workflows and public health infrastructures. Ultimately, the most successful players will be those who combine scientific excellence with pragmatic operational planning and collaborative go-to-market execution.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Nucleic Acid Testing Market, by Product Type

  • 8.1. Instruments
  • 8.2. Reagents & Kits
  • 8.3. Software & Services

9. Nucleic Acid Testing Market, by Technology

  • 9.1. Digital PCR
  • 9.2. Isothermal Amplification
  • 9.3. Microarray
  • 9.4. Next Generation Sequencing
  • 9.5. Real Time PCR

10. Nucleic Acid Testing Market, by Sample Type

  • 10.1. Blood
  • 10.2. Saliva
  • 10.3. Swabs
  • 10.4. Tissue
  • 10.5. Urine

11. Nucleic Acid Testing Market, by Application

  • 11.1. Clinical Diagnostics
  • 11.2. Drug Discovery
  • 11.3. Forensics
  • 11.4. Research
  • 11.5. Veterinary Diagnostics

12. Nucleic Acid Testing Market, by End User

  • 12.1. Academic Research Institutes
  • 12.2. Diagnostic Laboratories
  • 12.3. Hospitals & Clinics
  • 12.4. Pharmaceutical & Biotechnology Companies

13. Nucleic Acid Testing Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Nucleic Acid Testing Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Nucleic Acid Testing Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Nucleic Acid Testing Market

17. China Nucleic Acid Testing Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Abbott Laboratories
  • 18.6. Agilent Technologies, Inc.
  • 18.7. Becton, Dickinson and Company
  • 18.8. Bio-Rad Laboratories, Inc.
  • 18.9. bioMerieux SA
  • 18.10. Danaher Corporation
  • 18.11. F. Hoffmann-La Roche Ltd.
  • 18.12. Hologic, Inc.
  • 18.13. Illumina, Inc.
  • 18.14. PerkinElmer, Inc.
  • 18.15. QIAGEN N.V.
  • 18.16. Quest Diagnostics Incorporated
  • 18.17. Seegene Inc.
  • 18.18. Siemens Healthineers AG
  • 18.19. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL NUCLEIC ACID TESTING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL NUCLEIC ACID TESTING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES NUCLEIC ACID TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA NUCLEIC ACID TESTING MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY REAGENTS & KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY REAGENTS & KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY REAGENTS & KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY SOFTWARE & SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY SOFTWARE & SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY DIGITAL PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY DIGITAL PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY DIGITAL PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY MICROARRAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY MICROARRAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY MICROARRAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY REAL TIME PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY REAL TIME PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY REAL TIME PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY BLOOD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY BLOOD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY BLOOD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY SALIVA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY SALIVA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY SALIVA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY SWABS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY SWABS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY SWABS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY TISSUE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY TISSUE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY TISSUE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY URINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY URINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY URINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY DRUG DISCOVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY DRUG DISCOVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY FORENSICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY FORENSICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY FORENSICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY RESEARCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY RESEARCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY RESEARCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY VETERINARY DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY VETERINARY DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY VETERINARY DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS NUCLEIC ACID TESTING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS NUCLEIC ACID TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS NUCLEIC ACID TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS NUCLEIC ACID TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS NUCLEIC ACID TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS NUCLEIC ACID TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 80. NORTH AMERICA NUCLEIC ACID TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA NUCLEIC ACID TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA NUCLEIC ACID TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA NUCLEIC ACID TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA NUCLEIC ACID TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA NUCLEIC ACID TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA NUCLEIC ACID TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. LATIN AMERICA NUCLEIC ACID TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. LATIN AMERICA NUCLEIC ACID TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA NUCLEIC ACID TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA NUCLEIC ACID TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 91. LATIN AMERICA NUCLEIC ACID TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID TESTING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE NUCLEIC ACID TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE NUCLEIC ACID TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE NUCLEIC ACID TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE NUCLEIC ACID TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE NUCLEIC ACID TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE NUCLEIC ACID TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 104. MIDDLE EAST NUCLEIC ACID TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. MIDDLE EAST NUCLEIC ACID TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. MIDDLE EAST NUCLEIC ACID TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 107. MIDDLE EAST NUCLEIC ACID TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 108. MIDDLE EAST NUCLEIC ACID TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 109. MIDDLE EAST NUCLEIC ACID TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 110. AFRICA NUCLEIC ACID TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. AFRICA NUCLEIC ACID TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. AFRICA NUCLEIC ACID TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 113. AFRICA NUCLEIC ACID TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. AFRICA NUCLEIC ACID TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 115. AFRICA NUCLEIC ACID TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC NUCLEIC ACID TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC NUCLEIC ACID TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC NUCLEIC ACID TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC NUCLEIC ACID TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC NUCLEIC ACID TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC NUCLEIC ACID TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. ASEAN NUCLEIC ACID TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. ASEAN NUCLEIC ACID TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. ASEAN NUCLEIC ACID TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 126. ASEAN NUCLEIC ACID TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. ASEAN NUCLEIC ACID TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 128. ASEAN NUCLEIC ACID TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 129. GCC NUCLEIC ACID TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. GCC NUCLEIC ACID TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. GCC NUCLEIC ACID TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 132. GCC NUCLEIC ACID TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. GCC NUCLEIC ACID TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 134. GCC NUCLEIC ACID TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPEAN UNION NUCLEIC ACID TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPEAN UNION NUCLEIC ACID TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPEAN UNION NUCLEIC ACID TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPEAN UNION NUCLEIC ACID TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPEAN UNION NUCLEIC ACID TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPEAN UNION NUCLEIC ACID TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 141. BRICS NUCLEIC ACID TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. BRICS NUCLEIC ACID TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. BRICS NUCLEIC ACID TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 144. BRICS NUCLEIC ACID TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. BRICS NUCLEIC ACID TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 146. BRICS NUCLEIC ACID TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 147. G7 NUCLEIC ACID TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. G7 NUCLEIC ACID TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. G7 NUCLEIC ACID TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 150. G7 NUCLEIC ACID TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. G7 NUCLEIC ACID TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 152. G7 NUCLEIC ACID TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 153. NATO NUCLEIC ACID TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. NATO NUCLEIC ACID TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. NATO NUCLEIC ACID TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 156. NATO NUCLEIC ACID TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. NATO NUCLEIC ACID TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 158. NATO NUCLEIC ACID TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. UNITED STATES NUCLEIC ACID TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 161. UNITED STATES NUCLEIC ACID TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. UNITED STATES NUCLEIC ACID TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 163. UNITED STATES NUCLEIC ACID TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. UNITED STATES NUCLEIC ACID TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 165. UNITED STATES NUCLEIC ACID TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 166. CHINA NUCLEIC ACID TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 167. CHINA NUCLEIC ACID TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. CHINA NUCLEIC ACID TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 169. CHINA NUCLEIC ACID TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. CHINA NUCLEIC ACID TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 171. CHINA NUCLEIC ACID TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)